Investor Presentation First Nine Months of 2022
115
Investor presentation First nine months of 2022
EMEA at a glance
EMEA
Million
300
Diabetes trend
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
DKK
billion
25%
120
First nine months
of 2022
Sales
(mDKK)
Growth²
120%
Total GLP-13
10,661
39%
19%
I
I
Long-acting insulin4
5,407
4%
GLP-1
90
90%
200
Premix insulin5
1,986
-12%
34.18%1
Fast-acting insulin
4,874
-1%
60
100
260
195
158
60
3.25%1
Insulin
60%
Human insulin
1,512
-10%
Total insulin
13,779
-2%
30
30
OAD 30%
11.73%1
Other Diabetes care?
Diabetes care
536
-1%
24,976
12%
0
2021
0
0%
Obesity care8
2,575
96%
2030
2045
Aug
2017
Aug
2022
Diabetes & Obesity
27,551
17%
care
Population with diabetes
Diabetes growth rate
GLP-1 MS
-Insulin MS
-OAD MS
Rare disease⁹
5,171
-3%
Total
32,722
13%
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: Africa, Europe, Middle East and North Africa, South and Central
America, South East Asia and Western Pacific Source: International Diabetes
Federation: Diabetes Atlas 10th Edition 2021; EMEA: Europe, Middle East and Africa
1 CAGR calculated for 5-year period; Competitor insulin value market shares, as of
Aug 2022: Novo Nordisk 48%, Sanofi 32% and Eli Lilly 16%; Competitor GLP-1
value market shares, as of Aug 2022: Novo Nordisk 59%, Eli Lilly 38% and
AstraZeneca 3%; OAD: Oral anti-diabetic; MS: Market share; Source: IQVIA MAT,
Aug 2022 value figures
2 At Constant exchange rates; 3 Comprises Victoza®, Ozempic®, and RybelsusⓇ;
4 Comprises Tresiba®, XultophyⓇ and Levemir®; 5 Comprises RyzodegⓇ and
NovoMix® 6 Comprises FiaspⓇ and NovoRapidⓇ; 7 Comprises NovoNormⓇ and
needles; 8 Obesity care comprises SaxendaⓇ and WegovyⓇ; 9 Comprises
primarily NovoSeven®, Novo Eight® NovoThirteen®, Esperoct®, Refixia®,
Norditropin, Vagifem® and Activelle®View entire presentation